Institut Curie Announces formation of Honing Biosciences for the Development of Cell Therapies in Cancer and Chronic Diseases

Shots:

• Honing Biosciences will use CellTune molecular technology, that will initially emphasize on cancer immunotherapies particularly the CAR-T cells to target cancer cells
• The focus on this launch is to provide long-term care for cancer patients using a single injection of therapeutic cells, with the development of safe, effective and affordable approaches
• CellTune molecular technology monitors the dynamic distribution of proteins in cell-medicaments that will further help in developing new class of cell therapies

Click here to read full press release/ article | Ref: Institut Curie | Image: Business wire